0000000000234566

AUTHOR

Andrea Tannapfel

showing 7 related works from this author

Bilateral cystic pulmonary glial heterotopia and palatinal teratoma causing respiratory distress in an infant

2009

We report on a male infant with extensive, bilateral cystic and solid lung lesions who presented postnatally with respiratory distress caused by bilateral cystic lung lesions. Parenchyma-sparing resections were performed. Histology revealed the presence of neuroglial cell-lined cysts and glial nodules. In addition, a neural element containing palatinal teratoma was detected and excised. Based on previously published cases, the pathogenesis and clinical features of pulmonary neuroglial heterotopia are discussed.

AdultLung DiseasesMalePathologymedicine.medical_specialtyChoristomaFunctional LateralityPathogenesisGlial nodulesmedicineHumansAbnormalities MultipleRespiratory Distress Syndrome NewbornPalatal NeoplasmsLungRespiratory distressCystsbusiness.industryInfant NewbornTeratomaNeuroglial HeterotopiaBrainInfantHistologyGeneral Medicinemedicine.diseaseHeterotopia (medicine)medicine.anatomical_structurePediatrics Perinatology and Child HealthFemaleSurgeryTeratomaTomography X-Ray ComputedbusinessNeurogliaJournal of Pediatric Surgery
researchProduct

Immunotherapy: New Options in Gastrointestinal Cancers?

2019

Oncologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentGastroenterologyImmunotherapyImmunotherapy Gastrointestinal CancersText miningInternal medicinemedicineSurgeryddc:610businessInterdisciplinary DiscussionVisceral Medicine
researchProduct

The role of panitumumab in combination with ECX in perioperative chemotherapy of unselected patients with locally advanced gastroesophageal adenocarc…

2015

4040 Background: Perioperative chemotherapy (pCT) significantly improved survival of patients (pts) with locally advanced esophagogastric adenocarcinoma (la EGC). However, ~60% of pts will later di...

OncologyCancer Researchmedicine.medical_specialtybusiness.industryLocally advancedPhases of clinical researchImproved survivalCancermacromolecular substancesmedicine.diseaseSurgerycarbohydrates (lipids)stomatognathic diseasesOncologyInternal medicinePerioperative chemotherapyotorhinolaryngologic diseasesmedicinebacteriaPanitumumabAdenocarcinomabusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Endoscopic Management for Patients with Serrated Polyposis Syndrome is Feasible and Effective:

2014

Background and Study Aims: Serrated polyposis syndrome is a rare condition in which multiple serrated lesions develop all over the colon, which is thought to be associated with an increased risk for the development of cancer. The aim of this study was to investigate the feasibility of endoscopic treatment and standardised surveillance in patients with this increasingly recognised syndrome. Methods: From September 2010 to November 2013, consecutive patients were included in a prospective study. All patients underwent chromoendoscopy at first presentation and during surveillance. Follow-up examinations were carried out at 3 month intervals until complete clearance was achieved. Afterwards, pa…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industryColorectal cancerIncidence (epidemiology)GastroenterologyColonoscopymedicine.diseaseChromoendoscopySurgeryHyperplastic PolypCohortMedicineProspective cohort studybusinessCohort studyZeitschrift für Gastroenterologie
researchProduct

NEONAX trial: Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer, a phase II study of the AI…

2019

4128 Background: Survival in pancreatic cancer (PDAC) is still poor even after curatively intended resection. Perioperative treatment approaches improve outcome in various tumor entities. Data on perioperative treatment in resectable PDAC are limited and there is a debate whether neoadjuvant treatment might impair subsequent surgery by adding perioperative morbidity or mortality. Methods: NEONAX is a randomized phase II study (planned 166 patients) of perioperative gemcitabine/nab-paclitaxel (Arm A: 2 pre- and 4 post-operative cycles, Arm B: 6 cycles adjuvant) for patients with primarily resectable PDAC. Primary objective is DFS at 18 months after randomization. Secondary objectives are 3-…

Resectable Pancreatic CancerOncologyCancer Researchmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentPhases of clinical researchPerioperativeInterim analysismedicine.diseaseGemcitabine3. Good health03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicinePancreatic cancermedicinebusinessAdjuvant030215 immunologymedicine.drugNab-paclitaxelJournal of Clinical Oncology
researchProduct

S3-Leitlinie „Magenkarzinom” -

2011

Germanmedicine.medical_specialtyEsophagogastric cancerbusiness.industryGeneral surgeryGastroenterologyMEDLINElanguageMedicineGuidelinebusinesslanguage.human_languageZeitschrift für Gastroenterologie
researchProduct

S2k-Leitlinie nicht alkoholische Fettlebererkrankungen

2015

business.industryGastroenterologyMedicinebusinessZeitschrift für Gastroenterologie
researchProduct